Ogivri (Trastuzumab)

Trastuzumab, the active ingredient in Ogivri, is a monoclonal antibody presented as a 440 mg/20 ml solution for intravenous infusion use. It treats HER2‑positive breast cancer and HER2‑positive gastric/gastro‑esophageal junction adenocarcinoma in adult patients. GNH USA supplies Ogivri as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Ogivri as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Ogivri is a targeted therapy that acts on HER2‑positive cancers, a subgroup of tumors that overexpress the HER2 protein.

- Early‑stage HER2‑positive breast cancer: improves survival when combined with chemotherapy and surgery. - Metastatic HER2‑positive breast cancer: delays disease progression and extends overall survival. - HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma: used with chemotherapy in advanced disease.

Adverse reactions to Ogivri vary in frequency and severity.

Common Side Effects: - Fever - Nausea - Fatigue - Headache - Diarrhea - Infusion‑related reactions (e.g., chills, flushing)

Serious or Rare Side Effects: - Cardiac dysfunction or heart failure - Severe infusion reactions (anaphylaxis) - Pulmonary toxicity - Liver enzyme elevations - Thromboembolic events - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

When using Ogivri, clinicians should assess patient suitability and monitor for known risks.

- Cardiac assessment: perform baseline and periodic ejection‑fraction testing. - Infusion monitoring: observe patients during and after infusion for reactions. - Pregnancy and lactation: avoid use unless clearly needed; discuss risks with patient. - Concomitant therapies: review all concurrent medications for potential interactions. - Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Ogivri may interact with other agents, requiring clinical judgment.

Major Interactions (Avoid): - Anthracyclines (e.g., doxorubicin): increased risk of cardiac toxicity.

Moderate Interactions (Monitor Closely): - Other HER2‑targeted agents (pertuz pertuzumab) when combined. - CYP‑mediated drugs: limited data, monitor for unexpected effects. - Vaccines: live vaccines should be avoided during therapy. - Anticoagulants: watch for bleeding risk if thrombosis occurs. - Herbal supplements: potential immunomodulatory effects, assess use.